• Restore CFTR ProteinCompleted with Results

  Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation , protocol number AbbVie M19-530

  This study evaluated the safety and effectiveness of ABBV-3067, a CFTR modulator intended to improve CFTR function. ABBV-3067 was tested alone and in combination with another CFTR modulator, ABBV-2222. 

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    5

  • Length of Participation:

    3 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.